NEW drugs to treat breast cancer and Hodgkin’s lymphoma have been approved for use on the NHS in Scotland.
The Scottish Medicines Consortium (SMC) has accepted the new treatments after review through its patient and clinician engagement process.
Ribociclib (under the name Kisqali) was approved for advanced breast cancer in post-menopausal women, while pembrolizumab (Keytruda) was accepted for advanced Hodgkin’s lymphoma in patients who have failed to respond to previous treatments.
Dr Alan MacDonald, chairman of the SMC, said: “I am pleased we were able to accept these medicines for use by NHS Scotland.
“Ribociclib offers patients with advanced breast cancer the potential for valuable additional time with their families and may delay the need for chemotherapy treatment for some. For those with Hodgkin’s lymphoma, pembrolizumab offers the potential for some patients to go on to receive curative treatments, and a longer remission from disease for others.”
Angela Harris, head of Breast Cancer Care Scotland, said: “This tremendous decision brings people living with incurable breast cancer in Scotland on to an even footing with those in England.
“Ribociclib is an exciting milestone in treating this devastating disease, so it’s only right that access has been granted across the UK.
“When combined with other drugs, this innovative treatment can freeze the cancer’s growth for two years, giving vital extra time to hundreds of people in Scotland. And as Ribociclib often has fewer side effects, it offers the chance to live normal daily life for longer – from continuing work to making precious memories with friends and family.”
Meanwhile, the committee rejected the use of atezolizumab (Tecentriq) for advanced bladder cancer in patients unable to receive the current preferred treatment for that stage of the disease.
This was due to “uncertainties in the evidence” submitted by the drug company about the benefits of the medicine.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here